A series of novel hybrid molecules containing sulfanilamide and thiourea templates was designed and synthesized. These compounds were screened for antimicrobial and urease inhibitory activities. Some of the compounds revealed promising antibacterial and antifungalactivities. Fascinatingly, the majority of the compounds exhibited potential urease inhibitory activities with IC50 ranging from 0.20 to
A series of 3-aroyl-1-(4-sulfamoylphenyl)thiourea derivatives containing sulfonamide moiety were designed and synthesized as 15-lipoxygenase (15-LOX) inhibitors. Most synthesized compounds showed potent activity against soybean 15-LOX with IC50 values less than 25 mu M. The most potent compound 4c (3-methylbenzoyl derivative) with IC50 value of 1.8 mu M was 10-fold more potent than quercetin. Interestingly, compound 4c also showed the highest antioxidant activity, as determined by ferric reducing antioxidant power (FRAP) assay. Its capacity for reducing ferric ion was more than ascorbic acid. The viability assay of the selected compound 4c against oxidative stress-induced cell death in differentiated PC12 cells revealed that compound 4c significantly protected neurons against cell death in low concentrations. (C) 2014 Elsevier Masson SAS. All rights reserved.
Dai Guiyuan, Shi Daqing, Zhou Longhu, Wang Shuliang, Yingyong huaxue (Chin. J. Appl. Chem), 11 (1994) N 6, S 104-105
作者:Dai Guiyuan, Shi Daqing, Zhou Longhu, Wang Shuliang
DOI:——
日期:——
Selective c-FLIP Inhibitors as Anticancer Agents
申请人:Centre National de la Recherche Scientifique
公开号:US20190282563A1
公开(公告)日:2019-09-19
The present invention provides nine selective c-FLIP inhibitors that are useful in the treatment of cancer, alone or in combination with other chemotherapeutic agents, in particular with TRAIL-based chemotherapeutic agents. The present invention also relates to pharmaceutical compositions and kits comprising at least one of the nine selective c-FLIP inhibitors and their use in methods for the treatment of cancer, in particular to overcome chemoresistance or to improve sensitivity of tumors to TRAIL-based therapy.